Skip to main content

Table 6 Summary of other FDA-approved anticancer therapies investigated in current study by category and subcategory

From: Off-label use of cancer therapies in women diagnosed with breast cancer in the United States

Drug category

Drug name

Indicated for breast cancer

Labeled indications if not indicated for breast cancer (ICD-9-CM codes)

Initial FDA approval during study period

Hormone therapies

Anastrozole

Yes

 

1995

 

Exemestane

Yes

 

1999

 

Fluoxymesterone

Yes

 

1956

 

Fulvestrant

Yes

 

April 2002

 

Goserelin

Yes

 

1989

 

Letrozole

Yes

 

1997

 

Leuprolide

No

185

1985

 

Tamoxifen

Yes

 

1977

Targeted therapies

Bortezomib

No

 

May 2003

 

Erlotinib

No

 

November 2004

 

Imatinib

No

150-154, 158.0, 159.0, 159.8, 159.9, 171.5-171.9, 205.1, 205.9, 238.1, 239

May 2001

 

Sorafenib

No

155.0, 155.2, 197.7, 189.0, 189.8, 189.9, 198.0

December 2005

Immunotherapies

Aldesleukin

No

172, 189.0, 189.1, 189.8, 189.9, 198.0, 198.2

1992

 

Alemtuzumab

No

204.1, 204.9

May 2001

 

Bevacizumab

Yes1

153, 154, 162.2-162.5, 162.8, 162.9, 191, 197.0, 197.5, 198.3

February 20042

 

Cetuximab

No

140-149, 153, 154, 160, 161, 173.0-173.4, 195.0, 197.5

February 2004

 

Denileukin diftitox

No

202.1, 202.2

1999

 

Gemtuzumab ozogamicin

No

205.0, 205.9

2000

 

Panitumumab

No

153, 154, 197.5

September 2006

 

Rituximab3

No

200, 202, 204.1, 204.9, 714

1997

 

Thalidomide

No

0.17.1, 695.2, 203.0

1998

 

Trastuzumab

Yes

 

1998

  1. 1Breast cancer indication approved by FDA on February 22, 2008 and revoked in November 2011.
  2. 2Colorectal cancer indication approved in February 2004, Non-small cell lung carcinoma in October 2006, Glioblastoma in May 2009.
  3. 3Obtained FDA approval for Wegener’s Granulomatosis (WG) and Microscopic Polyngiitis (MPA) only in April 2011 (post-study period).